ROC curve analysis was used to evaluate the performance of CTSF and FBLN1 as serum biomarkers for diagnosing NSCLC BM, compared with the classical serum biomarkers for lung cancer (CEA, CA125, SCC, CYFRA211). Here, FBLN1 is linked to non-small cell lung carcinoma.